



Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes



Patrick Hanley^a, Jennifer A. Sutter^b, Noah G. Goodman^c, Yangzhu Du^d, Debora R. Sekiguchi^e, Wenzhao Meng^d, Michael R. Rickels^f, Ali Najji^g, Eline T. Luning Prak^{d,*}

^a Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^b Division of Endocrinology and Diabetes, East Carolina University Pediatrics Specialty Clinic, Greenville, NC, USA

^c Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

^d Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

^e Department of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada

^f Division of Endocrinology, Diabetes and Metabolism, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

^g Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

ARTICLE INFO

Article history:

Received 5 June 2017

Received in revised form 16 August 2017

Accepted with revision 22 September 2017

Available online 23 September 2017

Keywords:

B lymphocytes
Type 1 diabetes
TAC1
FasR

ABSTRACT

Although autoantibodies have been used for decades as diagnostic and prognostic markers in type 1 diabetes (T1D), further analysis of developmental abnormalities in B cells could reveal tolerance checkpoint defects that could improve individualized therapy. To evaluate B cell developmental progression in T1D, immunophenotyping was used to classify circulating B cells into transitional, mature naïve, mature activated, and resting memory subsets. Then each subset was analyzed for the expression of additional maturation-associated markers. While the frequencies of B cell subsets did not differ significantly between patients and controls, some T1D subjects exhibited reduced proportions of B cells that expressed transmembrane activator and CAML interactor (TAC1) and Fas receptor (FasR). Furthermore, some T1D subjects had B cell subsets with lower frequencies of class switching. These results suggest circulating B cells exhibit variable maturation phenotypes in T1D. These phenotypic variations may correlate with differences in B cell selection in individual T1D patients.

© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

T1D is an autoimmune disease that targets the insulin-producing beta cells in the pancreas. It affects approximately 1 in 300 people in the United States by 18 years of age. Epidemiologic studies show that the incidence of T1D has been increasing by 2–5% worldwide for unknown reasons [1]. B lymphocytes (B cells) appear to contribute to the pathogenesis of T1D. B cells are needed for the initiation of insulinitis and act as critical antigen presenting cells in the initiation of T cell-mediated autoimmune diabetes in the nonobese diabetic mouse model (NOD) [2–6]. In addition, a lack of B cells prevents insulinitis [7] and B cell depletion ameliorates T1D in mice [2,8]. Furthermore, a seminal study in humans demonstrated that therapy with the B cell depleting

antibody, rituximab (anti-CD20), slowed T1D disease after onset, but did not alleviate disease progression long-term [9,10].

In contrast to murine studies, the published literature on B cells in humans with T1D is sparse. An early study reported increased CD5 + CD19 + B cells in pediatric new onset T1D patients relative to patients with established disease for >30 days or healthy controls [11]. Increases in CD5 + B cells have also been observed in other disease states, including autoimmune disease [12]. In addition to B1-like B cells in humans [13], CD5 can also be expressed on transitional B cells [14] and pre-naïve B cells [15]. To fully distinguish B1-like B cells from these other cell subsets requires more in-depth flow cytometric analysis. In another study, B cell subsets were analyzed from cryopreserved peripheral blood mononuclear cells in healthy controls, adults with long standing T1D, new onset T1D patients, and age-matched unaffected siblings of other T1D patients [16]. No statistically significant differences were observed in the percentages of any of the B cell subsets. However, cryopreservation can induce significant changes in several critical B cell subsetting markers, including CD27 and CD38 [17].

Deng and colleagues used fresh blood [18] and larger patient cohorts to study circulating B lymphocyte subsets. They found that T1D patients had decreased percentages of B10 B cells (which they defined as CD19 + CD5 + CD1d^{hi}) and follicular B cells (CD19 +, CD23 +, CD21-),

Abbreviations: B cell receptor, BCR; Coefficient of variation, CV; Fas receptor, FasR or CD95; Mature activated B cells, MA; Mature naïve B cells, MN; Mean fluorescence intensity, MFI; Natural killer cells, NK; Nonobese diabetic mouse, NOD; Photomultiplier tube, PMT; Resting memory B cells, RM; Transmembrane activator and CAML interactor, TAC1 or CD267; Transitional B cells, TR; Type 1 diabetes, T1D.

* Corresponding author at: 405B Stellar Chance Labs, 422 Curie Blvd., Philadelphia, PA 19104, USA.

E-mail address: luning@pennmedicine.upenn.edu (E.T. Luning Prak).

and an increased percentage of marginal zone-like B cells (CD19+, CD21+, CD23-) compared to healthy controls. They also extended their analysis to patients with latent autoimmune diabetes and type 2 diabetes, and reported a negative association between the proportion of B10 cells and HbA1c levels. However, some of the markers used to define B cell subsets did not yield well-resolved populations. For example, marginal zone B cells in humans are typically also defined with CD27 expression [19]; the use of CD21 and CD23, based largely upon an analogy with murine B cell subsets (discussed in [20]), may not be sufficient.

Taken together, the previous analyses of circulating B cell subsets provide an unclear and inconsistent picture. In some patient groups, an increased frequency of CD5+ B cells is observed, but is unclear if the CD5+ B cells represent an autoimmune-prone B1-like population or enhanced production of early-stage B cells, as frequencies of CD5+ transitional cells are elevated in early childhood [21]. Other studies either failed to show differences between T1D subjects and controls, or showed differences, using limited subsetting schema [16,18]. Despite their technical limitations, the preceding data point to potential correlations between T1D and alterations in the peripheral B cell compartment. These data suggest that further evaluation of circulating B cell subsets is warranted.

We therefore revisited the definition of peripheral B cell subsets in T1D subjects using 11-color B cell subsetting panels that provide a more nuanced evaluation of subsets and their maturation process. By defining these subsets more thoroughly, we hope to gain better insights into how B cell maturation is altered in T1D. We also included a basic analysis of T lymphocytes and natural killer cells (NK) to determine if any T1D subjects with B cell abnormalities also had unusual T cell or NK cell phenotypes.

2. Materials and methods

2.1. Subjects

The Institutional Review Board at The University of Pennsylvania approved this study, and all subjects provided written informed consent to participate. Subjects were recruited from the Rodebaugh Diabetes Center and an outpatient clinic at the Hospital of the University of Pennsylvania. A total of 16 adult patients with established T1D and 16 nondiabetic control subjects were included in the final analysis. The patients and controls were studied at a single study visit using the same flow cytometry panels contemporaneously over a 10-month period. The control group of subjects was previously also used as healthy controls in two separate unrelated studies; one previous study evaluated B cell subsets and antibody repertoire in patients with systemic lupus erythematosus [22], while the other previous study examined the variability of circulating lymphocytes in adults over time [23]. The diagnosis for T1D was established by clinical characteristics including initial presentation, laboratory values such as reduced C-peptide and insulin-dependence. The demographic and clinical characteristics of the patients and controls are provided in Table 1.

2.2. Flow cytometry

Peripheral blood was collected in K₂EDTA tubes and processed within 24 h of collection for flow cytometry using the techniques described in [24]. Typically samples were drawn in the morning and processed and stained on the same day for flow cytometry (a detailed procedure for staining and flow cytometry is provided in [23]). Samples were analyzed by multicolor immunophenotyping using the antibody panels listed in Supplementary Table S1. The same lot numbers of antibodies used throughout the study. Data were acquired on an LSR flow cytometer (BD Biosciences, Franklin Lakes, NJ) in the Penn Flow Cytometry Shared Resource. Cytometer settings were standardized between runs using cytometer set-up and tracking beads (BD CST) and CVs in each of the detectors. PMT voltages were adjusted accordingly and

Table 1

Clinical and demographic features of study subjects. Data are represented as numbers. Numbers are shown with mean \pm standard deviation. Percentages are given in parentheses. Other = mixed race. T1D = type 1 diabetes. NA = not applicable. HbA1c = hemoglobin A1c.

	Controls (n = 16)	T1D (n = 16)
Female (%)	15 (94)	9 (56)
Male (%)	1 (6)	7 (44)
Age (years)	31.75 \pm 8.17	34.75 \pm 13.13
Age at diagnosis (years)	NA	15.50 \pm 10.43
Duration of diabetes (years)	NA	19.25 \pm 10.99
Caucasian (%)	9 (56)	13 (81)
African American (%)	4 (25)	1 (6)
Asian (%)	2 (13)	1 (6)
Hispanic (%)	1 (6)	0 (0)
Other (%)	0 (0)	1 (6)
HbA1c (%)	NA	7.10 \pm 0.97

baselines were re-established with new bead lots. Total event counts typically ranged from 500,000 to 1 million per tube. Data were analyzed with FlowJo v9.4.10 software (Treestar Inc., Ashland, OR). Gating schemes for T cell, NK cell and B cell subsets are shown in Supplementary Figs. S1a and S1b. The B cell subsets were defined as: transitional B cells, TR (CD27-, CD38++), mature naive B cells, MN (CD27-, CD38+), mature activated B cells, MA (CD27+, CD38+), plasmablasts, PB (CD27+++, CD38+++) and resting memory B cells, RM (CD27+, CD38-). Individual B cell subsets were further evaluated for IgM, CD10, CD138, CD21, CD23, CD95 (FasR), and CD267 (TACI) expression. In parallel, blood samples were drawn and processed for absolute lymphocyte counts by Coulter counting (complete blood count with electronic differential) at the William Pepper laboratory in the Hospital of the University of Pennsylvania.

2.3. Statistical analyses

The Mann Whitney test was used for the comparisons of values between groups for all data. To test for correlations between B cell subset fractions and subject age, body mass index or length of disease, Spearman correlations were used. Significance for all statistical tests was set at $p \leq 0.05$.

3. Results

3.1. General analysis of lymphocyte subsets

We evaluated the maturation of peripheral blood B cells as well as NK cells and CD4+ and CD8+ T cells in 16 adult patients with T1D and 16 non-diabetic control subjects using multicolor immunophenotyping. Our analysis focused mainly on the B lymphocyte compartment with 4 out of the 6 tubes tailored to more B specific markers, in addition to a T cell tube and a NK cell tube (panels are defined in Supplementary Table S1). The percentages of different major lymphocyte subsets analyzed in controls and T1D subjects are included in Table 2. The B cell analysis revealed no statistically significant differences in the percentages of CD19+, CD10+ CD27-, transitional (TR), mature naive (MN), mature activated (MA), resting memory (RM) or plasmablast subsets between controls and T1D subjects. However there was a reduced relative frequency of CD24++CD38++ B cells in T1D; these cells may correspond to a regulatory B cell population [25–27]. The analysis of CD3+ positive lymphocytes (T cells) demonstrated no statistically significant differences in CD4+ or CD8+ subsets between controls and T1D subjects. The non-B, non-T cell (CD3- CD19-) analysis revealed statistically significant differences in CD16+ CD56- and CD16- CD56+ presumed NK cells, with T1D subjects having higher percentages of both NK subsets. Using absolute cell counts (Supplementary Table S2), controls had a statistically significant increase in mature activated (MA; CD27+, CD38+) B cells compared to T1D subjects. T1D subjects also had

increased absolute counts of NK cells. Supplementary Table S3 provides the percentage and absolute cell count data for all subsets evaluated in all control subjects, and Supplementary Table S4 has the percentage and absolute cell count data for all subsets evaluated in all T1D subjects.

3.2. Multiple phenotypic abnormalities in B cell subsets in T1D

Based upon previous studies and mouse models of T1D [2–11], we hypothesized that T1D patients would harbor peripheral B cell subset differences compared to healthy controls. Consistent with this hypothesis, we observed several immunophenotypic differences between T1D subjects and controls. To reveal these differences, we began by analyzing the B cell subsets themselves and then characterizing additional phenotypic markers within each of the subsets. Circulating B cell subsets in humans can be classified into TR, MN, MA, and RM subsets on the basis of CD27 and CD38 expression (see [Materials and methods](#) and [Fig. 1a](#), and our previous use of this subsetting scheme to define B cell subsets in humans [23]). Based upon patterns of autoreconstitution following rituximab therapy and/or myeloablative chemotherapy, we know that TR cells are the first B cells to emigrate from the bone marrow following primary maturation, and enter the circulation [24,28–31]. Within the circulation, additional B cell subsets include MN, MA, RM, plasmablasts and anergic-enriched cells [32,33]. Starting with these subsets as a developmental framework, we next analyzed the progression of different B cell maturation antigens in each of the subsets. [Fig. 1b](#) shows the progression of TACI (CD267), FasR (CD95) and IgM expression with maturation from TR to RM B cell subsets. The proportion of TACI and FasR-expressing cells increases with maturation. In parallel, the proportion of IgM-expressing cells decreases, consistent with class switching to different antibody heavy chain isotypes.

With this developmental framework, we used 11-color immunophenotypic panels (Supplementary Table S1) to characterize B cell maturation in detail in T1D vs. control subjects. Individual subsets for peripheral blood B cells were further evaluated for TACI, FasR and IgM expression. Several statistically significant differences were observed among the B cell subsets between T1D subjects and control subjects (summarized in [Table 3](#)). There was a decreased percentage of

FasR positive MN and MA B cells in T1D subjects versus controls ([Fig. 2](#)). Additionally, there was a decreased fraction of B cells that were double positive for TACI and FasR in MN, MA and RM B cells in T1D subjects ([Fig. 2](#)). This consistent pattern of decreased TACI and FasR positive cells through different stages of peripheral B cell maturation is depicted with a string plot in [Fig. 3](#). Using 60% TACI + FasR + as the bottom of the normal range in RM cells in [Fig. 3](#), one can see that 7 out of the 16 T1D subjects have values below 60%. Several of these same T1D subjects also have lower TACI + FasR + B cell fractions in the MA subset. In the RM subset, there were also fewer class-switched (IgM-) TACI + B cells in seven T1D patients ([Fig. S2](#) and [Fig. S3](#)). When CD27 vs. IgM were used instead of CD27 vs. CD38 to subset the B cells, TACI and FasR differences between T1D and controls were similar, with most of the differences occurring in the mature B cell subsets ([Fig. S4](#)). When we computed the mean fluorescence intensities (MFIs) among positively staining cells in each B cell subset, there were no significant differences in the MFIs in TACI or FasR between T1D subjects and controls (Supplementary Table S5), suggesting that there are no major differences in cell surface antigen levels.

The fractions of the B cell subsets that differed significantly between T1D subjects and controls did not correlate with age, length of disease or the body mass index in the T1D subjects ([Fig. S5](#)). We wondered if a composite score of B cell subset abnormality would be more likely to correlate with these T1D subject characteristics. To test this idea we took the ten B cell subsets (and sub-subsets) that differed significantly between T1D subjects and controls and created a confidence interval (± 2 S.D.) for each subset's percentage representation, based upon the healthy control subject data ([Table 3](#)). Next, we arbitrarily assigned one point for each subject for each value that was outside of these confidence intervals. Then we summed the points for all ten subsets and plotted the sum (score) for each T1D subject versus the age, length of disease and body mass index ([Fig. S6](#)). No significant correlation was observed for any of these comparisons. Based upon this analysis, we conclude that age, length of disease and body mass index do not separate T1D patients who have B cell subset abnormalities from those who lack them.

4. Discussion

As B cells mature, they acquire surface TACI and FasR expression and undergo class switching from IgM to other heavy chain isotypes. In our flow cytometric analysis of circulating B cells, T1D subjects had fewer TACI and/or FasR expressing cells than control subjects. Some mature B cell subsets also had fewer class-switched B cells. These differences are present in multiple mature B cell subsets, as summarized in [Fig. 4](#). Taking all of these findings together, we propose that peripheral B cell maturation is disrupted in up to 50% of patients with longstanding T1D.

It is unclear why these B cell phenotypic abnormalities exist in T1D. They may be due to a developmental abnormality early in B cell development that persists through maturation, extending into the MN, MA and RM pools. However, if it were a selection defect, one might expect alterations in the B cell compartment size. Yet such alterations are minimal because absolute B cell counts, including the B cell subset counts, for the most part do not differ significantly between T1D and controls. Only the fractions of B cells expressing one or more of these maturation antigens within individual B cell subsets is altered. It is noteworthy that several of the significantly different B cell subsets demonstrated differences in FasR expression. In some subsets defined by both FasR and TACI, the abnormality could be due to a dominant effect in FasR. However, there are also FasR-independent differences, such as the reduced frequency of TACI + IgM- resting memory B cells in T1D subjects compared to controls. Given that there are changes in TACI, FasR and IgM (and combinations thereof), we favor the idea that there is a more general form of dysregulation as B cells mature in T1D.

Another non-mutually exclusive explanation for altered B cell subsets in T1D is that at each developmental stage TACI and FasR are

Table 2

Lymphocyte subset fractions. Lymphoid subsets are given as mean percentages \pm standard deviation of the parent population (denoted in bold font). The asterisk (*) indicates a statistically significant difference between T1D and control subjects, p -value < 0.05 (Mann Whitney test). Trans = transitional. MN = mature naive. MA = mature activated. RM = resting memory. PB = plasmablasts. Please see [Fig. 1a](#) for definitions of Trans, MA, MN, RM and PB, based on CD38 vs. CD27 staining.

Subset	Controls	T1D	p-Value
Lymphocytes			
CD19+	11.97 \pm 5.93	10.09 \pm 5.77	0.3962
CD3+	71.53 \pm 9.26	73.48 \pm 7.97	0.596
B cells (CD19+)			
CD10+ CD 27-	6.24 \pm 4.00	5.43 \pm 4.22	0.3659
Trans	5.25 \pm 1.88	6.76 \pm 3.12	0.2099
MN	68.68 \pm 12.64	70.53 \pm 9.49	0.7804
MA	18.82 \pm 9.81	13.41 \pm 5.66	0.0996
RM	4.41 \pm 3.76	5.46 \pm 6.05	0.8672
PB	0.61 \pm 0.72	0.47 \pm 0.28	0.6352
CD24+, CD38++	2.67 \pm 1.15	1.54 \pm 0.85	*0.0045
T cells (CD3+)			
CD4+	62.39 \pm 10.15	66.64 \pm 8.60	0.4909
CD8+	31.52 \pm 9.29	28.94 \pm 8.02	0.9932
CD4+/CD8+	0.83 \pm 0.89	0.48 \pm 0.22	0.2425
CD4-/CD8-	5.26 \pm 2.71	3.92 \pm 1.00	0.2661
NK cells (CD3- CD19-)			
CD56+	38.53 \pm 18.46	50.21 \pm 18.19	0.0865
CD56-	41.54 \pm 19.34	46.43 \pm 17.94	0.423
CD16+/CD56+	36.43 \pm 18.43	38.54 \pm 16.66	0.724
CD16+/CD56-	5.10 \pm 2.33	7.89 \pm 3.23	*0.0066
CD16-/CD56+	2.10 \pm 0.64	3.78 \pm 1.59	*0.0007




Fig. 1. a. Peripheral B cell subset scheme. Subsets were analyzed using multicolor immunophenotyping with cell surface markers that are associated with different stages of B cell development defined as: Transitional (Trans; IgM+, CD27-, CD38++, subset CD10+), Mature naïve (MN; CD27-, CD38+, IgM+), Mature Activated (MA; CD27+, CD38+), Plasmablasts (PB; CD27++, CD38++, CD20dim, CD138+), and Resting memory (RM; CD27+, CD38-). Number within each gate is % of parent (CD19+ lymphocytes). b. 4-color immunophenotyping progression of Fas, TACI and IgM. B cell peripheral maturation progression show from more naïve Trans B cells to more mature RM B cells. Subsets were first analyzed using multicolor immunophenotyping of cell surface markers that are associated with different stages of B cell development for Trans, MN, MA and RM cells. B cell subsets are based upon CD38 vs. CD27 staining: Trans (CD27-, CD38++), MA (CD27+, CD38+), MN (CD27-, CD38+), RM (CD27+, CD38-), and PB (CD27++, CD38++). The subsets were further studied with FasR, TACI, and IgM. The plots show increasing proportions of cells expressing FasR and TACI with maturation along with the decreased fractions of mature cells expressing IgM. Trans = transitional. MN = mature naïve. MA = mature activated. RM = resting memory. FasR = CD95. TACI = CD 267.

Table 3

Lymphocyte subset fractions that differ between T1D and control subjects. Data are represented as mean percentages \pm standard deviation. MN = mature naïve. MA = mature activated. RM = resting memory. Please see Fig. 1a for definitions of MA, MN and RM.

Subset	Controls	T1D	p-Value
MN CD95 +	5.80 \pm 2.78	2.68 \pm 1.92	0.0007
MN CD267-CD95 +	1.55 \pm 1.26	0.46 \pm 0.31	0.0009
MN CD267 + CD95 +	4.25 \pm 2.24	2.22 \pm 1.78	0.0041
MA CD95 +	40.08 \pm 11.20	30.93 \pm 10.43	0.0352
MA CD267 + CD95 +	36.35 \pm 9.46	26.49 \pm 9.63	0.0017
MA CD267- CD95-	4.73 \pm 3.48	9.92 \pm 8.03	0.0416
MA CD267- IgM +	1.63 \pm 1.55	4.86 \pm 5.22	0.0132
RM CD267 + CD95 +	76.01 \pm 5.88	59.21 \pm 19.91	0.0281
RM CD267 + IgM-	87.71 \pm 6.03	69.96 \pm 21.98	0.0378
CD24 +, CD38 ++	2.67 \pm 1.15	1.54 \pm 0.85	0.0045
CD16 + CD56-	5.10 \pm 2.33	7.89 \pm 3.23	0.0066
CD16-CD56 +	2.10 \pm 0.64	3.78 \pm 1.59	0.0007

differentially regulated in T1D compared to controls. However, T1D B cells that expressed TACI and/or FasR did so with similar staining intensity to B cells in control subjects. Nevertheless, there could be alterations in signaling pathways that could contribute to increased B cell activation, clonal expansion or survival without directly affecting TACI or FasR expression. It is also possible that the most robust differences in these markers or signaling pathways occurred in B cells that were counter-selected and are no longer available for analysis. Yet another possibility is that there is an independent disruption in tolerance and selection at multiple stages of peripheral B cell maturation in T1D. This possibility is unappealing because it is not parsimonious, but individuals with autoimmune conditions may have several immunologic perturbations that act in concert to yield a similar appearing end-state of autoimmunity.

Genetic factors may contribute to abnormal B cell developmental in T1D. An intriguing example is PTPN22, which is often referred to as

Lymphocyte tyrosine phosphatase (Lyp). Healthy carriers of the Lyp620W mutation harbor increased frequencies of autoimmune mature naïve B cells [34]. Mutations of PTPN22 such as Lyp620W are highly associated with several autoimmune diseases including T1D [35,36]. In a previous study, subjects with Lyp620W exhibited blunted BCR signaling in B cells and reduced apoptosis among transitional and anergic B cells. It is tempting to speculate that altered BCR signaling contributes to reduced expression of maturation and response-associated cell surface antigens such as FasR and TACI.

While shared genetic factors such as PTPN22 can contribute to disease risk in T1D, the phenotypic abnormalities we observed may also have functional consequences in and of themselves. The proportion of FasR-expressing cells was decreased in some B cell subsets in T1D, and also in combination with TACI in other B cell subsets. FasR is involved in apoptosis [37] and has been shown to be critical for clonal deletion in mice [38,39]. Yet paradoxically, in mice, FasR appears to contribute to the development of insulinitis as NOD mice that are deficient in either Fas ligand (FasL) (gld/gld) or FasR (lpr/lpr) have much less severe disease [40]. FasL or FasR deficient mice appear to have an expansion of IL-10 expressing CD5 + B cells with regulatory properties [41]. In humans, the best-characterized disease with known Fas mutations is autoimmune lymphoproliferative syndrome [42], in which polyreactive and somatically mutated antibody-expressing memory B cells accumulate [37]. Given the complex landscape of potential central [22,43] and peripheral B cell and T cell tolerance defects in T1D [4], and the complexity of FasR itself, it is possible that alterations in FasR expression or its regulation could impact both forms of tolerance.

Abnormal TACI signaling has also been linked to autoimmune disease [44–46], contributing to B cell activation abnormalities in patients with common variable immunodeficiency [47,48]. NOD mice exhibit increased TACI expression compared to B6 mice and this increase is accompanied by plasma cell differentiation and class switching to IgG and IgA [49]. In contrast, our analysis of human T1D subjects reveals a




Fig. 2. B cell subsets for TACI and FasR. Shown are the percentages of TACI+, FasR+, or doubly positive TACI+ and FasR+ cells in the MN, MA and RM B cell subsets for control and T1D subjects. Please see Fig. 1a for B cell subset scheme and definitions of MA, MN and RM based on CD38 vs. CD27 staining. Three asterisks (***) indicate a p-value that is <0.001; (**) indicate a p-value that is <0.01 and (*) a p-value that is <0.05. T1D = type 1 diabetes. MN = mature naïve. MA = mature activated. RM = resting memory. TACI = CD267. FasR = CD95.




Fig. 3. String plot of B cells positive for both FasR and TACI. String plot depicting TACI and FasR expression in B cells. Columns indicate B cell subsets ordered from least mature TR cells (left) to more mature RM cells (right). Percentages of doubly positive TACI+ and FasR+ cells in the TR, MN, MA and RM B cell subsets for control and T1D subjects. Please see Fig. 1a for B cell subset scheme and definitions of TR, MA, MN and RM based on CD38 vs. CD27 staining. One asterisk (*) indicates a statistically significant difference between this population in T1D subjects compared to control subjects, $p < 0.05$. T1D = type 1 diabetes. TR = transitional. MN = mature naïve. MA = mature activated. RM = resting memory. TACI = CD267. FasR = CD95.

lower proportion of TACI-expressing mature B cells. The difference in these results could reflect anatomic compartment differences (most of the mouse work sampled splenic B cells) or differences between NOD and human T1D. TACI can also be a negative regulator of immune responses, inhibiting B cell expansion [50–52]. TACI deficiency in mice and humans can cause hypogammaglobulinemia, reduced immune responses to encapsulated bacteria and influenza [53–55], and, in some cases, increased evidence of autoimmunity accompanied by lymphoproliferation [51,56]. Curiously, humans with TACI deficiency, while sometimes having immunodeficiency, can also mount robust antibody responses [57]. It will be interesting to determine in future studies if clonal expansion of memory B cells is increased in T1D. TACI also influences differentiation of B cells into plasma cells [53,57–59] and induces IgG and IgA class switch recombination [60–62]. Varying and inconsistent global alterations of IgG or IgA antibodies have been reported in T1D patients [63–68], T1D-associated autoantibodies that are measured clinically are comprised of IgG, whereas IgA autoantibodies have not been well described [69,70].

Our study has some limitations. The patients analyzed were older and most had longstanding T1D. Therefore the abnormalities we

observe could be a consequence rather than a cause of their autoimmune disease. However, we did not observe a correlation between the length of disease and the B cell subset abnormalities, either in isolation or as a composite arbitrary score of overall B cell subset abnormality. In the future it will be important to analyze new-onset or at-risk populations such as patients with one or multiple diabetes-related autoantibodies to see if differences in FasR and TACI are also found in these populations. The possibility that alterations in TACI or FasR expression in B cells could serve as a predictive biomarker for disease development would represent an important advance. Second, the sample size was modest and T1D is a heterogeneous disease [71,72]. However, despite the heterogeneity in T1D, the differences noted in our analysis were seen in multiple B cell subsets and in multiple patients. Third, our analysis was focused on the peripheral blood. The blood may not accurately reflect the biology of the disease. In this connection, a recent paper [73] describes an expansion of CD5+ FasL^{hi} cells in the spleens of human subjects with T1D, suggesting that in tissue-based B cells (as in the NOD mouse studies [40,41]), FasR could be a driver of autoimmunity by inhibiting regulatory B cells, rather than having a suppressive role. This is very different from what we




Fig. 4. Summary of peripheral B cell maturation abnormalities in T1D. Schematic highlighting peripheral B cell maturation in control subjects (top) and T1D subjects (bottom). B cell subsets are arranged from the least mature transitional cells (TR) on the left, followed by mature naïve (MN) to the more mature subsets, mature activated (MA), plasmablasts (PB) and resting memory (RM) cells, on the right. B cell subsets are defined immunophenotypically, as shown in Fig. 1a. Subsets with maturation antigen differences (TACI, FasR, and/or IgM) in T1D compared to controls are denoted by the red checked pattern. Antibodies (Ab) are in black and T1D-associated autoantibodies are colored in red.

observe in the peripheral blood. The functional role of CD5 + B cells in T1D warrants further investigation.

Despite decades of research, the most reliable predictive B cell markers for T1D are diabetes-associated autoantibodies, which are evident after tolerance has been broken, and are not good markers of clinical responses to immunologic interventions as they can vary significantly, even without interventions [74–76]. While it is unclear how the B cell maturation abnormalities that we have observed have arisen in T1D, understanding their mechanistic underpinnings could provide novel biomarkers for this disease [77]. Such biomarkers could potentially offer earlier diagnostic markers of disease, help to better stratify at-risk patients, and provide more specific ways to monitor response to B cell targeted immunotherapies in clinical trials.

5. Conclusion

Subjects with longstanding T1D exhibited multiple immunophenotypic abnormalities in circulating B cell subsets compared to healthy controls. Abnormalities included decreased percentages of FasR positive mature B cells, a decreased percentage of double-expressing TACI and FasR positive mature B cells, and a decreased percentage of class-switched TACI positive B cells. These findings show that some subjects with T1D have abnormal development in the TACI and FasR activation markers as B cells mature, which may contribute to the development or maintenance of autoimmunity. A more detailed analysis of memory B cell subsets is warranted to better understand the immunologic abnormalities in T1D.

Acknowledgments

We thank the study subjects and the University of Pennsylvania Flow Cytometry Shared Resource and the Human Immunology Core for assistance. PH and JS were supported by an NIH T32 training grant: 5T32DK063688-12; JS was also supported by a postdoctoral fellowship award from the JDRF; MR, AN, NG and ELP were supported by NIH U01 DK-070430. Additional support was received from P30-CA016520 and from the Human Metabolism Resource of the Institute for Diabetes, Obesity & Metabolism.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.clim.2017.09.021>.

References

- [1] D.M. Maahs, et al., Epidemiology of type 1 diabetes, *Endocrinol. Metab. Clin. N. Am.* 39 (3) (2010) 481–497.
- [2] H. Noorchashm, et al., B-cells are required for the initiation of insulinitis and sialitis in nonobese diabetic mice, *Diabetes* 46 (6) (1997) 941–946.
- [3] D.V. Serreze, et al., B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice, *J. Immunol.* 161 (8) (1998) 3912–3918.
- [4] H. Noorchashm, et al., I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice, *J. Immunol.* 163 (2) (1999) 743–750.
- [5] P.L. Kendall, et al., Tolerant anti-insulin B cells are effective APCs, *J. Immunol.* 190 (6) (2013) 2519–2526.
- [6] D.V. Serreze, P.A. Silveira, The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes, *Curr. Dir. Autoimmun.* 6 (2003) 212–227.
- [7] D.V. Serreze, et al., B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice, *J. Exp. Med.* 184 (5) (1996) 2049–2053.
- [8] C.Y. Hu, et al., Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice, *J. Clin. Invest.* 117 (12) (2007) 3857–3867.
- [9] M.D. Pescovitz, et al., Rituximab, B-lymphocyte depletion, and preservation of beta-cell function, *N. Engl. J. Med.* 361 (22) (2009) 2143–2152.
- [10] M.D. Pescovitz, et al., B-lymphocyte depletion with rituximab and beta-cell function: two-year results, *Diabetes Care* 37 (2) (2014) 453–459.
- [11] G. De Filippo, et al., Increased CD5 + CD19 + B lymphocytes at the onset of type 1 diabetes in children, *Acta Diabetol.* 34 (4) (1997) 271–274.
- [12] K. Hayakawa, et al., Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies, *Proc. Natl. Acad. Sci. U. S. A.* 81 (8) (1984) 2494–2498.
- [13] D.O. Griffin, N.E. Holodick, T.L. Rothstein, Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20 + CD27 + CD43 + CD70, *J. Exp. Med.* 208 (1) (2011) 67–80.
- [14] G.P. Sims, et al., Identification and characterization of circulating human transitional B cells, *Blood* 105 (11) (2005) 4390–4398.
- [15] J. Lee, et al., Identification and characterization of a human CD5 + pre-naive B cell population, *J. Immunol.* 182 (7) (2009) 4116–4126.
- [16] W.S. Thompson, et al., Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes, *Clin. Exp. Immunol.* 177 (3) (2014) 571–585.
- [17] A. Klippert, B. Neumann, C. Stahl-Hennig, Comparative phenotypical analysis of B cells in fresh and cryopreserved mononuclear cells from blood and tissue of rhesus macaques, *J. Immunol. Methods* 433 (2016) 59–68.
- [18] C. Deng, et al., Altered peripheral b-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults, *Diabetes Care* 39 (3) (2016) 434–440.
- [19] S. Weller, et al., Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire, *Blood* 104 (12) (2004) 3647–3654.
- [20] B. Srivastava, et al., Characterization of marginal zone B cell precursors, *J. Exp. Med.* 202 (9) (2005) 1225–1234.
- [21] E.T. Luning Prak, et al., Age-related trends in pediatric B-cell subsets, *Pediatr. Dev. Pathol.* 14 (1) (2011) 45–52.
- [22] A.K. Panigrahi, et al., RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes, *J. Exp. Med.* 205 (13) (2008) 2985–2994.
- [23] D.R. Sekiguchi, et al., Circulating lymphocyte subsets in normal adults are variable and can be clustered into subgroups, *Cytometry B Clin. Cytom.* 80 (5) (2011) 291–299.
- [24] J.A. Sutter, et al., A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery, *Clin. Immunol.* 126 (3) (2008) 282–290.
- [25] P.A. Blair, et al., CD19 (+)CD24 (hi)CD38 (hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients, *Immunity* 32 (1) (2010) 129–140.
- [26] K.A. Newell, et al., Identification of a B cell signature associated with renal transplant tolerance in humans, *J. Clin. Invest.* 120 (6) (2010) 1836–1847.
- [27] F. Flores-Borja, et al., CD19 + CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation, *Sci. Transl. Med.* 5 (173) (2013) 173ra23.
- [28] D.R. Sekiguchi, et al., Analysis of B cell subsets following pancreatic islet cell transplantation in a patient with type 1 diabetes by cytometric fingerprinting, *J. Immunol. Methods* 363 (2) (2011) 233–244.
- [29] C. Liu, et al., B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates, *Nat. Med.* 13 (11) (2007) 1295–1298.
- [30] J.H. Anolik, et al., B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny, *Clin. Immunol.* 122 (2) (2007) 139–145.
- [31] M.A. Avanzini, et al., B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27 + B cells, *Exp. Hematol.* 33 (4) (2005) 480–486.
- [32] M. Perez-Andres, et al., Human peripheral blood B-cell compartments: a crossroad in B-cell traffic, *Cytom. B Clin. Cytom.* 78 (Suppl. 1) (2010) S47–60.
- [33] Y.C. Wu, D. Kipling, D.K. Dunn-Walters, The relationship between CD27 negative and positive B cell populations in human peripheral blood, *Front. Immunol.* 2 (2011) 81.
- [34] L. Menard, et al., The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans, *J. Clin. Invest.* 121 (9) (2011) 3635–3644.
- [35] Y.R. Li, et al., Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases, *Nat. Med.* 21 (9) (2015) 1018–1027.
- [36] D.J. Rawlings, X. Dai, J.H. Buckner, The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human, *J. Immunol.* 194 (7) (2015) 2977–2984.
- [37] A. Janda, et al., Disturbed B-lymphocytes selection in autoimmune lymphoproliferative syndrome, *Blood* (2016).
- [38] Z. Hao, et al., Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis, *Immunity* 29 (4) (2008) 615–627.
- [39] Y. Takahashi, H. Ohta, T. Takemori, Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire, *Immunity* 14 (2) (2001) 181–192.
- [40] A.V. Chervonsky, et al., The role of Fas in autoimmune diabetes, *Cell* 89 (1) (1997) 17–24.
- [41] Z. Xiao, et al., Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulinitis development, *Am. J. Pathol.* 179 (2) (2011) 725–732.
- [42] A. Worth, A.J. Thrasher, H.B. Gaspar, Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype, *Br. J. Haematol.* 133 (2) (2006) 124–140.
- [43] N. Chamberlain, et al., Rituximab does not reset defective early B cell tolerance checkpoints, *J. Clin. Invest.* 126 (1) (2016) 282–287.
- [44] F.S. Hoffmann, et al., The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity, *J. Immunol.* 194 (2) (2015) 542–552.
- [45] J.A. Gross, et al., TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BlyS, *Immunity* 15 (2) (2001) 289–302.
- [46] J.A. Gross, et al., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, *Nature* 404 (6781) (2000) 995–999.

- [47] U. Salzer, et al., Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans, *Nat. Genet.* 37 (8) (2005) 820–828.
- [48] N. Romberg, et al., CVID-associated TACI mutations affect autoreactive B cell selection and activation, *J. Clin. Invest.* 123 (10) (2013) 4283–4293.
- [49] V.S. Banday, et al., Increased expression of TACI on NOD B cells results in germinal centre reaction anomalies, enhanced plasma cell differentiation and immunoglobulin production, *Immunology* 149 (3) (2016) 297–305.
- [50] D. Sakurai, et al., TACI attenuates antibody production costimulated by BAFF-R and CD40, *Eur. J. Immunol.* 37 (1) (2007) 110–118.
- [51] D. Seshasayee, et al., Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BlyS receptor, *Immunity* 18 (2) (2003) 279–288.
- [52] M. Yan, et al., Activation and accumulation of B cells in TACI-deficient mice, *Nat. Immunol.* 2 (7) (2001) 638–643.
- [53] G.T. Mantchev, et al., TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens, *J. Immunol.* 179 (4) (2007) 2282–2288.
- [54] G.U. von Bulow, J.M. van Deursen, R.J. Bram, Regulation of the T-independent humoral response by TACI, *Immunity* 14 (5) (2001) 573–582.
- [55] A.I. Wolf, et al., Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI, *J. Clin. Invest.* 121 (10) (2011) 3954–3964.
- [56] K. Wamatz, R.E. Voll, Pathogenesis of autoimmunity in common variable immunodeficiency, *Front. Immunol.* 3 (2012) 210.
- [57] S. Tsuji, et al., TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen, *J. Clin. Invest.* 124 (11) (2014) 4857–4866.
- [58] S. Tsuji, et al., TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow, *Blood* 118 (22) (2011) 5832–5839.
- [59] X. Ou, S. Xu, K.P. Lam, Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival, *Proc. Natl. Acad. Sci. U. S. A.* 109 (38) (2012) 15401–15406.
- [60] E. Castigli, et al., TACI and BAFF-R mediate isotype switching in B cells, *J. Exp. Med.* 201 (1) (2005) 35–39.
- [61] D. Sakurai, et al., TACI regulates IgA production by APRIL in collaboration with HSPG, *Blood* 109 (7) (2007) 2961–2967.
- [62] B. He, et al., The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88, *Nat. Immunol.* 11 (9) (2010) 836–845.
- [63] S. Hoddinott, et al., Immunoglobulin levels, immunodeficiency and HLA in type 1 (insulin-dependent) diabetes mellitus, *Diabetologia* 23 (4) (1982) 326–329.
- [64] F. Cerutti, et al., Selective IgA deficiency in juvenile-onset insulin-dependent diabetes mellitus, *Pediatr. Med. Chir.* 10 (2) (1988) 197–201.
- [65] S. Giza, et al., Prevalence of selective immunoglobulin A deficiency in Greek children and adolescents with type 1 diabetes, *World J. Pediatr.* 12 (4) (2016) 470–476.
- [66] D. Greco, F. Maggio, Selective immunoglobulin a deficiency in type 1 diabetes mellitus: a prevalence study in Western sicily (Italy), *Diabetes Metab. J.* 39 (2) (2015) 132–136.
- [67] Z. Pietruska, et al., Serum immunoglobulins and various components of complement in patients with insulin-dependent diabetes mellitus, *Przegl. Lek.* 46 (3) (1989) 338–341.
- [68] W.I. Smith Jr., et al., Immunopathology of juvenile-onset diabetes mellitus. I. IgA deficiency and juvenile diabetes, *Diabetes* 27 (11) (1978) 1092–1097.
- [69] V. Lampasona, D. Liberati, Islet Autoantibodies, *Curr. Diabetes Rep.* 16 (6) (2016) 53.
- [70] C.E. Taplin, J.M. Barker, Autoantibodies in type 1 diabetes, *Autoimmunity* 41 (1) (2008) 11–18.
- [71] M.A. Atkinson, G.S. Eisenbarth, A.W. Michels, Type 1 diabetes, *Lancet* 383 (9911) (2014) 69–82.
- [72] J.B. Bollyky, et al., Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective, *Diabetes Metab. Res. Rev.* 31 (6) (2015) 588–594.
- [73] A. Saxena, et al., Expansion of FasL-expressing CD5+ B cells in type 1 diabetes patients, *Front. Immunol.* 8 (2017) 402.
- [74] E. Bonifacio, Predicting type 1 diabetes using biomarkers, *Diabetes Care* 38 (6) (2015) 989–996.
- [75] E. Bonifacio, et al., Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation, *J. Immunol.* 163 (1) (1999) 525–532.
- [76] J. Lebastchi, K.C. Herold, Immunologic and metabolic biomarkers of beta-cell destruction in the diagnosis of type 1 diabetes, *Cold Spring Harb. Perspect. Med.* 2 (6) (2012) a007708.
- [77] J.L. Browning, B cells move to centre stage: novel opportunities for autoimmune disease treatment, *Nat. Rev. Drug Discov.* 5 (7) (2006) 564–576.